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Abstract The iboga alkaloids are a class of naturally
occurring and synthetic compounds, some of which modify
drug self-administration and withdrawal in humans and
preclinical models. Ibogaine, the prototypic iboga alkaloid
that is utilized clinically to treat addictions, has been
associated with QT prolongation, torsades de pointes and
fatalities. hERG blockade as IKr was measured using the
whole-cell patch clamp technique in HEK 293 cells. This
yielded the following IC50 values: ibogaine manufactured
by semisynthesis via voacangine (4.09 ± 0.69 lM) or by
extraction from T. iboga (3.53 ± 0.16 lM); ibogaine’s
principal metabolite noribogaine (2.86 ± 0.68 lM); and
voacangine (2.25 ± 0.34 lM). In contrast, the IC50 of
18-methoxycoronaridine, a product of rational synthesis
and current focus of drug development was [50 lM.
hERG blockade was voltage dependent for all of the
compounds, consistent with low-affinity blockade. hERG
channel binding affinities (Ki) for the entire set of com-
pounds, including 18-MC, ranged from 0.71 to 3.89 lM,
suggesting that 18-MC binds to the hERG channel with
affinity similar to the other compounds, but the interaction
produces substantially less hERG blockade. In view of the
extended half-life of noribogaine, these results may relate
to observations of persistent QT prolongation and cardiac
arrhythmia at delayed intervals of days following ibogaine
ingestion. The apparent structure–activity relationships
regarding positions of substitutions on the ibogamine
skeleton suggest that the iboga alkaloids might provide an
informative paradigm for investigation of the structural
biology of the hERG channel.
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Introduction
The iboga alkaloids are a class of approximately 80 known
naturally occurring and synthetic monoterpene indole
alkaloids that are defined structurally on the basis of a
common ibogamine skeleton (Fig. 1) [1, 2]. Some iboga
alkaloids reportedly reduce the self-administration of drugs
of abuse and opiate withdrawal symptoms in animal
models and humans [3, 4]. Ibogaine, the prototypic iboga
alkaloid is used in medical and nonmedical settings for the
treatment of substance use disorders. Ibogaine is illegal in
the USA and several EU countries due to its classification
as a hallucinogen, and unregulated in most of the rest of the
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world, where it is neither illegal nor officially approved.
The collective settings of ibogaine use have been termed a
‘‘medical subculture’’ [5] or a ‘‘great uncontrolled experi-
ment’’ [6]. Nonetheless, in view of evidence for a novel
mechanism of action, the search for targets of iboga alka-
loids may be informative regarding the neurobiology of
addiction and the development of fundamentally innova-
tive treatment [3, 4, 7, 8].
Ibogaine is most often used for the specific indication of
opioid detoxification, and typically administered as a large
single dose in the range of 10–25 mg/kg [5, 9, 10]. Fatalities
have occurred temporally related to the use of ibogaine.
Nineteen such fatalities are known to have occurred between
1991 and 2009 [11], most of which were associated with
commonly abused substances and preexisting medical
comorbidities, particularly cardiovascular. Subsequent
clinical reports have demonstrated prolongation of the QT
interval and/or polymorphic ventricular tachyarrhythmias
(PVTs) [12–15] including torsades de pointes (TdP) [16].
The major cause of drug-induced TdP is the blockade of
a voltage-gated cardiac potassium channel [17], the pore-
forming subunit of which is encoded by the human ether-a-
go-go-related gene (hERG) [18]. The hERG channel con-
ducts the efflux of potassium from the cardiac myocyte that
is the basis of the rapid delayed rectifier current (IKr)
during the repolarization phase of the cardiac action
potential. hERG channel blockade impairs cardiac repo-
larization, resulting in prolongation of the QT interval and
PVTs, including TdP. Consistent with observations of QT
prolongation and TdP, Ibogaine blocks the hERG channel
with reported IC50 in the low micromolar range [19, 20].
Ibogaine is most frequently used in the hydrochloride
form and is produced by one of two methods. One method
involves extraction from the root bark of the West African
shrub Tabernanthe iboga Baill. (Apocynaceae family).
This has been the most frequent method of manufacture in
the present settings of ibogaine use [5]. The purity of this
material is typically approximately 95 %, which raises the
toxicological question of trace impurities as an additional
possible determinant of hERG blockade. More recently,
Ibogaine HCl has become available that has been produced
by the route of semisynthesis via voacangine (Fig. 1),
which can yield higher purity on the order of C99.5 %.
Noribogaine is ibogaine’s principal metabolite, the
product of demethylation of ibogaine (Fig. 1) via hepatic
cytochrome P450 2D6 (CYP2D6). The half-life (T1/2) of
ibogaine in humans is estimated to be 4–7 h [9, 21], and the
T1/2 of noribogaine is apparently considerably longer than
that of the parent compound, possibly on the order of days
[22–24]. The question of hERG blockade by noribogaine is
of interest in view of observations of persistent QT pro-
longation and arrhythmia for days following the ingestion
of ibogaine [13, 15, 16].
18-Methoxycoronaridine (18-MC) is a product of
rational pharmaceutical synthesis that differs from ibogaine
at three of the 21 positions on the ibogamine skeleton
(Fig. 1). 18-MC is reported to produce less hERG blockade
than ibogaine [25]. The National Institute on Drug Abuse
(NIDA) has recently committed over 6 million USD to
support preclinical testing and chemical manufacturing and
control work intended to eventually enable clinical trials
for the development of 18-MC [8]. However, ibogaine is
the iboga alkaloid that has been commonly used for the
treatment of addiction.
In the present study, we evaluated hERG blockade and
binding affinities for the hERG channel of iboga alkaloids.
We evaluated blockade of the hERG channel by noribog-
aine, and compared ibogaine produced by extraction from
T. iboga versus a sample of higher purity produced by
semisynthesis via voacangine. Collectively, the data from
this set of compounds appear to allow some tentative
structural hypotheses regarding positions on the ibogamine




Ibogaine HCl (purity = 95 %) produced by extraction of
T. iboga root bark was obtained from Slater & Frith Ltd,
Wroxham Norwich, UK. Ibogamine was the major impu-
rity in this sample, with lesser amounts of tabernanthine
and ibogaline. Ibogaine HCl (purity = 99.5 %) obtained
by conversion from voacangine, and voacangine (purity
[99 %) were obtained from Phytostan Enterprises, Inc.,
Montreal, Quebec. Noribogaine (purity = 99.2 %) was
Fig. 1 Chemical structures of ibogaine, noribogaine, voacangine, and
18-MC. The positions of R1, R2, and R3 on the ibogamine parent
structural skeleton are numbered 10, 16, and 18, respectively,
according to the Le Men and Taylor system
The current–voltage relationships of IKr were tested
after depolarizations from -60 to 50 mV in 10 mV
increments from a holding potential of -80 mV in the
absence or presence of the iboga alkaloids. Ibogaine from
either source, and noribogaine and voacangine was all
evaluated at a concentration of 3 lM. Because the effect on
IKr of 18-MC at a concentration of 3 lM was negligible,
we tested the effect of 18-MC at a concentration of 10 lM.
Radioligand Binding Assays
The radioligand binding assay methodology has been
described elsewhere [26, 27]. Briefly, membrane pellets for
radioligand binding assays were prepared from HEK 293 cells
stably expressing hERG channels. Inhibition of [3H]Dofeti-
lide (2 nM) binding to the hERG channel was carried out in
the absence (total binding) and presence of increasing con-
centrations of iboga alkaloids (0.1–10,000 nM) in 96-well
plates, with final volume of 125 ml per well-binding buffer
(10 mM HEPES, 135 mM NaCl, 5 mM KCl, 0.8 mM
MgCl2, 1 mM EGTA, 1 mg/ml BSA, pH 7.4). Bound radi-
oligand was captured by filtration onto glass fiber filter paper,
and radioactivity retained on the filter was counted in a Mi-
croBeta TriLux plate counter. Results were analyzed in
GraphPad Prism with the built-in one-site inhibition binding
function to obtain binding affinity (Ki). Affinity values are
presented as mean from a minimum of two independent
assays, each in triplicate.
Statistical Analysis
Pclamp9.2 (Axon Instruments) and Excel (Microsoft, Seat-
tle, Wash) were used for data acquisition and analysis. Data
are presented as mean ± SE. An unpaired Student t test and
one-way ANOVA were used to compare means. Values of
p\ 0.05 were considered statistically significant.
Results
Concentration–Response Relationships
99.5 % ibogaine manufactured by semisynthesis via vo-
acangine blocked hERG with IC50 4.09 ± 0.69 lM
(n = 14) (Figs. 2a, 3a). IC50 for hERG blockade by 95 %
ibogaine manufactured by extraction from T. iboga was
3.53 ± 0.16 lM (n = 10) (Fig. 3b). There was no differ-
ence for IC50 of ibogaine produced by the two respective
methods of manufacturing (t = 0.67, df = 23; p = .51).
Noribogaine blocked the hERG channel with an IC50 of
2.86 ± 0.68 lM (n = 11, Figs. 2b, 3c). Similar to iboga-
ine and noribogaine, voacangine blocked the hERG chan-
nel with an IC50 of 2.25 ± 0.34 lM (n = 6) (Fig. 3d), IC50
obtained from Slater & Frith Ltd. 18-MC HCl (purity
[99 %) was from Obiter Research LLC, Champaign, IL. 
The purities of iboga alkaloids are stated on certificates of 
analyses and verified by the available manufacturer’s 
HPLC documentation and/or HPLC–MS or GC–MS in the 
laboratory of Martin Kuehne, Department of Chemistry, 
University of Vermont, Burlington, Vermont [7].
Transfection in HEK Cells
hERG cDNA was subcloned into the pcDNA3.1 vector 
(Invitrogen, Carlsbad, USA). Human embryonic kidney 
293 (HEK293) cells were cultured in minimum essential 
medium (MEM) supplemented with 10 % fetal bovine 
serum, 1 mM sodium pyruvate, 0.1 mM non-essential 
amino acid solution, 100 U/ml penicillin, and 100 mg/ml 
streptomycin sulfate in 5 % CO2 incubator at 37 C. 
HEK293 cells were transiently transfected with 0.9 lg of  
WT-hERG using Lipofectamine according to the manu-
facture’s instruction (Invitrogen, California, USA). 0.15 lg 
of eGFP plasmid was co-transfected to monitor transfection 
efficacy. To examine the blocking effect of ibogaine and its 
derivatives on hERG channel, HEK293 cells were har-
vested at 36 h after transfection and seeded onto a glass 
coverslip. After 12–24 h, the cell-attached coverslips were 
used for electrophysiological recordings.
Electrophysiology
Membrane currents were measured using whole-cell patch 
clamp procedures with Axopatch 200B amplifiers (Axon 
Instruments, Foster City, CA, USA). Internal pipette 
solution contained 130 mM KCl, 1 mM MgCl2, 5 mM  
EGTA, 5 mM MgATP, and 10 mM HEPES with pH 7.2 
adjusted with KOH. External solutions consisted of 
137 mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 
10 mM glucose, and 10 mM HEPES with pH 7.4 adjusted 
with NaOH. Recordings were made at room temperature.
Concentration–response curves were tested for iboga 
alkaloids. The IKr current was elicited from a holding 
potential of -80 mV by a depolarizing pulse to 20 mV for 
4 s and then followed by a repolarization step to -50 mV 
for 4 s to evoke tail current (Itail). The IKr current was first 
recorded when superfused with extracellular solution 
without drug (control condition), then the same cell was 
superfused with extracellular solution containing a giving 
concentration of the tested drug, and current was recorded 
after steady state was achieved in the presence of drug. The 
tail current recorded in the presence of drug is compared 
with the current recorded without drug, and the decreased 
percentage is marked as the blocking effect of the tested 
drug. Concentration–response curves were fitted with the 
following equation: I/Imax = 1/1 ? [(drug)/IC50]n.
Fig. 2 Effect on hERG
blockade of: a ibogaine (99.5 %
purity), and b noribogaine.
Original current recording in the
same cell with control (red),
1 lM (black), 10 lM (blue),
and after washout (green).
c Effect of 18-MC on hERG
blockade: (left) original current
recording in the same cell with
control (red), 10 lM (black),
100 lM (teal), and after
washout (green); (right) 18-MC
at concentrations of 10 and
100 lM reduced IKr by
12.8 ± 1.8 and 57.8 ± 4.7 %,
respectively (Color figure
online)
Fig. 3 Concentration-response curves for hERG blockade by iboga alkaloids: a ibogaine 99.5 % purity produced by semisynthesis via
voacangine, b ibogaine 95 % purity produced by extraction from T. iboga root bark, c noribogaine, and d vocangaine
did not differ among ibogaine produced by either manu-
facturing method, noribogaine, and voacangine (one-way
ANOVA, F3,27 = 1.53; p = .22).
In contrast to the other compounds, 18-MC showed
much less potent hERG blockade. Concentrations of 10 and
100 lM decreased IKr current by 12.8 ± 1.8 and
57.8 ± 4.7 %, respectively (n = 9) (Fig. 2c). We observed
precipitation with higher concentrations of 18-MC in Ty-
rode solution, which limited the accuracy of the measure-
ment of IC50. We estimate that the IC50 of 18-MC is
between 50 and 100 lM.
Current–Voltage Relationships
hERG blockade was studied across the range of voltages
between-60 mV and 50 mV in 10 mV increments (Fig. 4).
Tail current density did not differ significantly among con-
trol and drug-treated conditions at any voltages below
10 mV. Tail current density differed significantly among
control and drug-treated conditions at 10 mV (one-way
ANOVA, F5,56 = 2.78; p = 0.025), and differences were
all highly significant at voltages of 20 mV or greater
(p\ 0.001).
hERG blockade was voltage dependent for all of the
compounds. However, there was no significant difference
between the control and 10 lM 18-MC at any voltage. The
values for blockade of tail current at 20 mV by 99.5 %
ibogaine, and 95 % ibogaine were 42 ± 5.2 % (n = 6) and
45 ± 5.6 % (n = 4), respectively. Noribogaine,
voacangine, and 18-MC blocked of tail current at 20 mV
with respective values of 52 ± 6.4 % (n = 5), 54 ± 2.7 %
(n = 9) and 13 ± 3.0 % (n = 7).
Radioligand Binding Assays
Ki values (lM) were as follows: ibogaine (99.5 % pur-
ity) = 0.71 ± 0.13; noribogaine = 1.96 ± 0.36; voacan-
gine = 3.89 ± 0.69; and 18-MC = 3.12 ± 0.60.
Discussion
In the present study, we evaluated hERG blockade by
ibogaine, 18-MC, noribogaine, and voacangine utilizing
the whole-cell patch clamp technique. Noribogaine blocked
the hERG channel with potency comparable to that of its
parent compound. Ibogaine produced by extraction from T.
iboga root bark or as a purer product of semisynthesis via
voacangine produced similar hERG blockade. Collectively,
the set of compounds suggests possible structure–function
inferences regarding the relatively less hERG blockade
associated with 18-MC.
The values for IC50 of ibogaine and noribogaine appear
clinically relevant. The IC50 values for 99.5 %, 95 % ibo-
gaine, and noribogaine were 4.09, 3.53, and 2.86 lM,
respectively. In a sample of 24 subjects that were orally
administered ibogaine dosages of 10 mg/kg, mean peak
blood levels for ibogaine and noribogaine, respectively,
Fig. 4 Current–voltage
relationships for hERG
blockade by iboga alkaloids.
Left original recordings of IKr
under control conditions (for
each compound, the control
recording is to the left of the test
compound recording) with
extracellular solution containing
3 lM ibogaine 99.5 % purity
(a), ibogaine 95 % purity (b),
noribogaine (c), and vocangaine
(d); and 10 lM 18-MC (e).
Right the current–voltage curve
of the tail currents under control
conditions (empty symbol) and
with 3 lM ibogaine 99.5 %,
ibogaine 95 %, noribogaine,
and voacangine; and 10 lM
18-MC. n = 4 to 9 cells
were 2.4 and 3.2 lM [9]. A protocol consisting of single
large orally administered dose is clinically representative;
ibogaine is commonly administered for opiate detoxification
as a single dose in the range of 10–25 mg/kg [5, 10, 11].
From a postmortem series of 19 fatalities, the subset of 10
cases in which blood ibogaine levels was available, the mean
was 7.6 lM (range 0.77–30 lM), and in the two cases for
which they were available, noribogaine levels were 13.4 and
18.8 lM [11]. Although the interpretation of levels from
postmortem studies may be complicated by redistribution,
and taking into account that ibogaine is 65 % protein bound
[25], ibogaine or noribogaine may produce significant hERG
channel blockade at clinically relevant concentrations [25].
There is apparently no published data regarding the fraction
of noribogaine that is protein bound.
The clearance of noribogaine is prolonged relative to
ibogaine. A study on 24 human volunteers that excluded
CYP2D6 slow metabolizers found ibogaine T1/2 = 7.45 h
following the administration of a fixed dose of 800 mg
ibogaine HCl [9]. In this same sample, the half-life of
noribogaine was reported as not quantifiable, but individual
24 h blood versus concentration curves published sepa-
rately appear to indicate T1/2 well beyond one day [22, 23].
In a subsequent study in which human volunteers received
single doses of noribogaine ranging from 3 to 60 mg, T1/2
for noribogaine ranged from 28 to 49 h [24]. A single dose
of 60 mg noribogaine produced a mean peak blood level of
0.39 lM [24], and repeated administration would be
expected to produce higher steady state levels in view of
the extended T1/2 of noribogaine.
Clinically, hERG blockade by noribogaine, in view of
its extended T1/2 may relate to the occurrence of arrhyth-
mias or fatalities at an extended interval following the
ingestion of ibogaine. Deaths at intervals of days after
ingestion of ibogaine occur at a time when it would be
expected that most ibogaine would be metabolized to
noribogaine. For example, in a recent case report, QTc
remained[500 ms for 4 days following administration of
ibogaine [15]. In another case of well-characterized TdP
and pause-dependent PVT, runs of PVT persisted into the
fifth hospital day [16]. In the series of 19 fatalities, the
interval between ingestion and death ranged from 1.5 to
76 h, with a mean of 24 h [11].
Ibogaine HCl 95 % produced by extraction from T. ib-
oga root bark is the purity and method of manufacture that
has been most commonly used clinically [5]. This 95 %
ibogaine and the 99.5 % ibogaine produced by semisyn-
thesis via voacangine produced similar levels of hERG
blockade. From a toxicological perspective, the very sim-
ilar hERG blockade by either ibogaine sample appears to
indicate that the observed hERG blockade is due to ibo-
gaine itself and not to a trace impurity. Ibogaine hydro-
chloride form either source utilized in this study is
relatively pure in contrast to crude alkaloid extracts or
dried root bark from T. iboga [5, 11]. The frequency of
fatalities [5, 11, 28, 29] or serious cardiac arrhythmias [12–
14] in cases involving the use of alkaloid extracts or dried
T. iboga root bark suggests the possibility that these crude
forms may contain toxicologically relevant compounds in
addition to ibogaine.
Our findings of IC50 values of 4.09 lM and 3.53 lM,
respectively, for 99.5 % ibogaine and 95 % ibogaine agree
well with a previous study that reported an IC50 value for
ibogaine of 4 lM in TSA-201 cells heterologously
expressing hERG [19]. However, our finding of an 18-MC
IC50 value [50 lM differs somewhat from a previously
reported value of 14.9 lM [25]. This previously published
value for the IC50 of 18-MC was reportedly determined as
in the prior study that had reported on ibogaine [19].
However, the more salient feature may be the apparent
general agreement of our present findings with the previ-
ously published data indicating that 18-MC produces sub-
stantially less hERG blockade than ibogaine [19, 25].
The concept of ‘‘repolarization reserve’’ [30] clinically
contextualizes hERG blockade to multifactorial determi-
nants of cardiac rhythm instability. Typically, drug-
induced TdP occurs in the clinical setting of multiple
factors in addition to hERG blockade that diminish cardiac
stability [17]. Among fatalities temporally related to
ingestion of ibogaine, factors in addition to hERG blockade
that diminish repolarization reserve are frequently present.
Hypokalemia appears to be particularly important, as in a
case involving severe depletion of potassium due to very
aggressive use of cathartics as part of a ‘‘cleansing’’ regi-
men prior to treatment, an example that also illustrates the
idiosyncratic hazards associated with the unconventional
settings in which ibogaine is often administered [16].
Additional factors that commonly diminish repolariza-
tion reserve in chronic substance-related disorders include
various co-ingestants, cardiac disease, and systemic medi-
cal conditions such as liver or respiratory disease, seizures,
hypomagnesemia, or withdrawal from cocaine or alcohol
[17, 31–33]. These factors are frequently present in cases
of arrhythmia or fatalities associated with the ingestion of
ibogaine [11–13, 16]. Additional case reports have
involved other significant, diverse comorbidities, such as a
patient with an automatic implantable cardioverter defi-
brillator [28, 29], or Marfan’s syndrome [14]. A recent case
of a cardiac arrest with postanoxic encephalopathy in a
previously healthy 26-year-old man who ingested a very
high dose of 32 mg/kg [34] appears to be an exception
from the general association of ibogaine-related deaths or
severe cardiac adverse events with medical co-morbidities
and co-ingestants, and may indicate a dose-related effect.
Bradycardia importantly potentiates the risk of drug-
induced TdP [17, 30]. It has been observed in association
binding affinity. Interestingly, although this substitution
might influence binding affinity, it is not apparently a
critical determinant of the effect of hERG blockade, as
indicated by the widely divergent values of IC50 for vo-
acangine and 18-MC of 2.25 and [50 lM respectively.
18-MC binds to the hERG channel with an affinity that is
within a comparable range to that of the other compounds,
but the interaction apparently produces substantially less
hERG blockade.
The question of the modulation of hERG blockade by
substitutions on the ibogamine skeleton should be addres-
sed further by expanding the query to additional iboga
alkaloids in future studies. The apparent structure–activity
relationships observed in this study suggest that it may be
productive to apply computational biological approaches to
investigation of the iboga alkaloid ‘‘toxicophore,’’ includ-
ing in silico modeling of the iboga alkaloid interaction with
the hERG channel [46].
In the present study, we used whole-cell patch clamp
technique to investigate the potency of hERG blockade by
iboga alkaloids. The effect of iboga alkaloids on the gating
properties of the hERG channel should be a focus for future
study. Future research should extend the model beyond
single cells to include interactions among cardiac myocytes
using a myocardial wedge preparation, which allows
simultaneous recordings of endocardial and epicardial
transmembrane action potential in order to evaluate trans-
mural dispersion [47]. The whole animal heart model [48,
49] may be useful approach to the investigation of iboga-
ine’s clinically salient effect of bradycardia, which appears
to substantially potentiate the risk of TdP.
Conclusions
The low micromolar IC50 values of ibogaine and norib-
ogaine appear clinically relevant regarding levels that have
been associated with QT prolongation, arrhythmia, and/or
fatalities. The prolonged clearance of noribogaine may be a
mediating factor in persistent QTc prolongation, arrhyth-
mia, and fatalities at delayed intervals following the
ingestion of ibogaine on the order several days. Collec-
tively, the set of iboga alkaloids investigated in this study
indicates structure–activity relationships regarding posi-
tions on the ibogamine skeleton and hERG blockade, and
suggest that this alkaloid class might provide an informa-
tive paradigm for investigation of the structural biology of
the hERG channel.
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with ibogaine in both animal models [35–38] and humans 
[11, 16, 39, 40]. The mechanism by which ibogaine causes 
bradycardia remains unknown, and is an interesting and 
clinically significant toxicological question for future 
study. Although an older literature suggested inhibition of 
acetylcholinesterase as a basis for bradycardia, this is not 
supported by contemporary assay techniques [41]. Ibogaine 
binds to sodium channels in animal brain tissue with low 
micromolar affinity [4], and there is an association of 
sodium channel blockade with bradycardia [42]. However, 
in human, Nav1.5 sodium channels heterologously 
expressed in TSA-201 cells both ibogaine and 18-MC
produce minimal blockade ([100 lM) [25].
hERG channel blockade was voltage dependent for all 
of the compounds tested. Blockade of hERG channels by 
low-affinity ligands tends to be voltage dependent [43], in 
contrast to the little or no voltage-dependence commonly 
exhibited by high-affinity hERG channel blockers.
The data appear to indicate structure–activity relation-
ships regarding positions of substitutions on the ibogamine 
skeleton and hERG blockade. As indicated in Fig. 1, there 
are only three positions on the iboga alkaloid structural 
skeleton that distinguish among the set of iboga alkaloids 
evaluated in this study. Utilizing the LeMen and Taylor 
system for numbering the ibogamine skeleton [44, 45], 
voacangine differs from ibogaine with regard to the car-
bomethoxy group at the 16 position (R2 in the figure). 
Voacangine and ibogaine show an equivalent effect of 
hERG antagonism, suggesting that the carbomethoxy 
group of 18-MC at position 16 is not protective regarding 
hERG blockade. Ibogaine and voacangine have a methoxy 
group, and noribogaine has a hydroxyl group at position 10 
(R1 in the figure), and all have comparable hERG antago-
nism. An oxygen atom could form a noncovalent electro-
static interaction, or in the case of noribogaine, a hydrogen 
bond with a polar amino acid residue in the binding site of 
the channel, raising the possibility that oxygen-containing 
substitutions at position 10 might be a mediator of hERG 
blockade. 18-MC, in contrast to the other compounds has 
only a hydrogen at position 10. The methoxy group at 
position 18 (R3 in the figure) is another possible structural 
determinant of the substantially smaller effect of 18-MC on 
hERG blockade.
The hERG channel binding affinities for the entire set of 
compounds, including 18-MC fell into a relatively 
restricted range from 0.71 to 3.89 lM. Nonetheless, there 
is a fivefold difference between the top and bottom of this 
approximately 3 lM range. The two compounds at the 
upper end of this range, voacangine and 18-MC have 
similar values of Ki of 3.89 and 3.12 lM, respectively, and 
share the common attribute of a carbomethoxy group at the 
same position 16 (R2 in the figure), suggesting that this 
specific substitution might be a determinant of decreased
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